- Home
- XFOR
as 10-28-2025 9:37am EST
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 84.3M | IPO Year: | N/A |
| Target Price: | $34.17 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.35 - $26.83 | Next Earning Date: | 11-12-2025 |
| Revenue: | $32,774,000 | Revenue Growth: | 5721.31% |
| Revenue Growth (this year): | 1307.51% | Revenue Growth (next year): | -41.70% |
Latest X4 Pharmaceuticals Inc. News
XFOR Breaking Stock News: Dive into XFOR Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
GlobeNewswire
5 days ago
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
Zacks
6 days ago
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
GlobeNewswire
2 months ago
Sitryx appoints Adam Mostafa as Chief Financial Officer
GlobeNewswire
4 months ago
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
GlobeNewswire
5 months ago
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
GlobeNewswire
5 months ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
5 months ago
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
Compare XFOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XFOR X4 Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.